Eric Schwartz - Integra LifeSciences President
| IART Stock | USD 18.88 0.23 1.20% |
President
Mr. Eric I. Schwartz is Corporationrationrate Vice President, General Counsel, Secretary of the Company. Mr. Schwartz joined Integra in November 2018. Before coming to Integra, Mr. Schwartz was the general counsel of Globus Medical, a global orthopedic medical devices company, where he led several strategic transactions, including the largest acquisition in its company history. Prior to that, Mr. Schwartz served as the Chief Operating Officer and Chief Legal Officer of CardioVIP, a venturebacked health care services company. From 2004 through 2006 he served as general counsel at Animas Corporationrationration, playing a key role in its sale to Johnson Johnson. Following the transaction, Mr. Schwartz assumed the role of assistant general counsel at JJ, supporting several highgrowth businesses within the companys medical devices division. He also served on the management boards of McNeil Nutritionals and Ethicon Biosurgery since 2018.
| Age | 55 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 1100 Campus Road, Princeton, NJ, United States, 08540 |
| Phone | 609 275 0500 |
| Web | https://www.integralife.com |
Integra LifeSciences Management Efficiency
The company has return on total asset (ROA) of 0.0351 % which means that it generated a profit of $0.0351 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0147 %, meaning that it created $0.0147 on every $100 dollars invested by stockholders. Integra LifeSciences' management efficiency ratios could be used to measure how well Integra LifeSciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.04 in 2024. Return On Capital Employed is likely to gain to 0.05 in 2024. At this time, Integra LifeSciences' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 2 B in 2024, whereas Total Current Liabilities is likely to drop slightly above 158.9 M in 2024.Similar Executives
| Found 12 records | PRESIDENT Age | ||
| James Cunniff | Electromed | 58 | |
| David Bailey | Orthopediatrics Corp | 45 | |
| Gregg Sutton | SurModics | 64 | |
| Keyna Skeffington | LivaNova PLC | 61 | |
| Gregory Odle | Orthopediatrics Corp | 54 | |
| Stephanie Bolton | LivaNova PLC | 42 | |
| MBAMSHA CHE | Orthopediatrics Corp | 52 | |
| Daniel Gerritzen | Orthopediatrics Corp | 54 | |
| Paul Buckman | LivaNova PLC | 68 | |
| Ryan Miller | LivaNova PLC | N/A | |
| Joseph Hauser | Orthopediatrics Corp | 41 | |
| Franco Poletti | LivaNova PLC | N/A | |
Management Performance
| Return On Equity | 0.0147 | ||||
| Return On Asset | 0.0351 |
Integra LifeSciences Leadership Team
Elected by the shareholders, the Integra LifeSciences' board of directors comprises two types of representatives: Integra LifeSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Integra. The board's role is to monitor Integra LifeSciences' management team and ensure that shareholders' interests are well served. Integra LifeSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Integra LifeSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth Burhop, Chief Scientific Officer, Corporate Vice President | ||
| Ruth Fleming, Vice Marketing | ||
| Eric Schwartz, Corporate Vice President General Counsel, Secretary | ||
| Lea Knight, Executive CFO | ||
| Mathieu Aussermeier, Investor Finance | ||
| Robert Davis, President of Specialty Surgical Solutions and Corporate VP | ||
| Maria Platsis, Sr Devel | ||
| William Compton, Chief VP | ||
| Jeffrey Mosebrook, Principal Accounting Officer, Vice President Corporate Controller | ||
| Susan Krause, Corporate Officer | ||
| Stuart Hart, Corporate Officer | ||
| Mark Jesser, Corporate Officer | ||
| Jan Witte, CEO President | ||
| Laurene Isip, Vice Relations | ||
| Michael McBreen, Executive Surgical | ||
| Carrie Anderson, CFO and Principal Financial Officer, Corporate Vice President | ||
| Stuart Essig, Chairman of the Board | ||
| Jessica Smith, Corporate Officer | ||
| Stephen Leonard, Corporate Chain |
Integra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Integra LifeSciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0147 | ||||
| Return On Asset | 0.0351 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 3.2 B | ||||
| Shares Outstanding | 77.58 M | ||||
| Shares Owned By Insiders | 3.19 % | ||||
| Shares Owned By Institutions | 94.60 % | ||||
| Number Of Shares Shorted | 4.4 M | ||||
| Price To Earning | 26.94 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.